Crinetics Pharmaceuticals (CRNX) investor relations material

Key presentations and strategic updates

• Highlighted the successful launch of PALSONIFY (paltusotine) for acromegaly, generating $5.4 million in initial revenue, over 200 patient enrollments, and more than 125 unique prescribers, with strong diversity across academic and community settings.

• Emphasized a robust pipeline with nine+ clinical programs, including advanced trials for carcinoid syndrome, CAH, Cushing's disease, and a novel oncology candidate (CRN09682), all developed in-house, with IP protection into the 2040s.

• Announced positive CHMP recommendation for European approval of paltusotine, with potential EU launch by mid-year and a country-by-country commercialization strategy.

• Reported strong payer receptivity, with over 50% of patients quickly reimbursed and expectations to achieve three-quarters of coverage within nine months of launch.

• Raised additional capital, securing funding into 2030 to support ongoing and future clinical and commercial initiatives, and built a fully integrated pharmaceutical company.

Strategic vision and mission

• Aims to be the global leader in endocrine therapeutics, pioneering new treatments for improved patient outcomes.

• Focuses on a broad range of endocrine diseases, including acromegaly, carcinoid syndrome, CAH, Cushing's syndrome, NETs, hyperparathyroidism, Graves' disease, ADPKD, and obesity.

Clinical development and pipeline milestones

• Paltusotine is in phase 3 for carcinoid syndrome, aiming to improve symptom control over current injectable therapies, with endpoints focused on reducing flushing and diarrhea.

• Atumelnant, an ACTH receptor antagonist, is in phase 3 for CAH and phase 2/3 for Cushing's disease, with a differentiated composite endpoint targeting both androgen normalization and glucocorticoid dose reduction.

• Phase II data for atumelnant in CAH showed promising results, including no liver toxicity and sustained androgen reduction in long-term extension studies.

• CRN09682, a novel SST2-targeted cytotoxic small molecule for neuroendocrine tumors, is in first-in-human dose escalation (BRAVESST2 study), with potential for dose expansion pending data.

• Preclinical programs targeting TSH and PTH receptors are advancing, with potential IND filings and clinical entry as early as next year.